Literature DB >> 29947871

Abnormal bone turnover in individuals with low serum alkaline phosphatase.

L López-Delgado1, L Riancho-Zarrabeitia2, M T García-Unzueta3, J A Tenorio4, M García-Hoyos1, P Lapunzina4, C Valero1, J A Riancho5.   

Abstract

The clinical spectrum of hypophosphatasia (HPP) is broad and variable within families. Along severe infantile forms, adult forms with mild manifestations may be incidentally discovered by the presence of low alkaline phosphatase (ALP) activity in serum. However, it is still unclear whether individuals with persistently low levels of ALP, in the absence of overt manifestations of HPP, have subclinical abnormalities of bone remodeling or bone mass. The aim of this study was to obtain a better understanding of the skeletal phenotype of adults with low ALP by analyzing bone mineral density (BMD), bone microarchitecture (trabecular bone score, TBS), and bone turnover markers (P1NP and ß-crosslaps). We studied 42 individuals with persistently low serum ALP. They showed lower levels of P1NP (31.4 ± 13.7 versus 48.9 ± 24.4 ng/ml; p = 0.0002) and ß-crosslaps (0.21 ± 0.17 versus 0.34 ± 0.22 ng/ml, p = 0.0015) than individuals in the control group. There were no significant differences in BMD, bone mineral content, or TBS. These data suggest that individuals with hypophosphatasemia have an overall reduction of bone turnover, even in the absence of overt manifestations of HPP or low BMD. We evaluated bone mineral density (BMD), bone microarchitecture, and bone turnover markers in patients with low serum levels of alkaline phosphatase. Our results show that these patients have low bone remodeling even in the absence of BMD abnormalities, thus supporting the recommendation of avoiding antiresorptives such as bisphosphonates in these subjects.

Entities:  

Keywords:  Bone mineral density; Bone turnover markers; Hypophosphatasemia; Hypophosphatasia

Mesh:

Substances:

Year:  2018        PMID: 29947871     DOI: 10.1007/s00198-018-4571-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  20 in total

1.  Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice.

Authors:  C Wennberg; L Hessle; P Lundberg; S Mauro; S Narisawa; U H Lerner; J L Millán
Journal:  J Bone Miner Res       Date:  2000-10       Impact factor: 6.741

2.  "Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia.

Authors:  Roger A L Sutton; Steven Mumm; Stephen P Coburn; Karen L Ericson; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

Review 3.  Physiological role of alkaline phosphatase explored in hypophosphatasia.

Authors:  Michael P Whyte
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

Review 4.  Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges.

Authors:  Michael P Whyte
Journal:  J Bone Miner Res       Date:  2017-01-31       Impact factor: 6.741

5.  Alkaline phosphatase activity in the osteoclasts induced by experimental tooth movement.

Authors:  Y Nakamura; T Tanaka; Y Wakimoto; K Noda; Y Kuwahara
Journal:  J Electron Microsc (Tokyo)       Date:  1991-12

6.  Molecular evolution of the tissue-nonspecific alkaline phosphatase allows prediction and validation of missense mutations responsible for hypophosphatasia.

Authors:  Jérémie Silvent; Barbara Gasse; Etienne Mornet; Jean-Yves Sire
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

7.  Skeletal mineralization defects in adult hypophosphatasia--a clinical and histological analysis.

Authors:  F Barvencik; F Timo Beil; M Gebauer; B Busse; T Koehne; S Seitz; J Zustin; P Pogoda; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2011-01-26       Impact factor: 4.507

8.  Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia.

Authors:  K N Fedde; L Blair; J Silverstein; S P Coburn; L M Ryan; R S Weinstein; K Waymire; S Narisawa; J L Millán; G R MacGregor; M P Whyte
Journal:  J Bone Miner Res       Date:  1999-12       Impact factor: 6.741

9.  Clinical, radiographic and biochemical characteristics of adult hypophosphatasia.

Authors:  T Schmidt; H Mussawy; T Rolvien; T Hawellek; J Hubert; W Rüther; M Amling; F Barvencik
Journal:  Osteoporos Int       Date:  2017-05-25       Impact factor: 4.507

Review 10.  Alkaline Phosphatase and Hypophosphatasia.

Authors:  José Luis Millán; Michael P Whyte
Journal:  Calcif Tissue Int       Date:  2015-11-21       Impact factor: 4.333

View more
  10 in total

Review 1.  Proposing a clinical algorithm for better diagnosis of hypophosphatasia in resource-limiting situations.

Authors:  Sreyanko Sadhukhan; Poonam Mehta; Singh Rajender; Sushil Kumar Gupta; Naibedya Chattopadhyay
Journal:  Osteoporos Int       Date:  2022-07-01       Impact factor: 4.507

2.  Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study.

Authors:  Nicola Hepp; Anja Lisbeth Frederiksen; Morten Duno; Niklas Rye Jørgensen; Jens-Erik Beck Jensen
Journal:  Osteoporos Int       Date:  2022-08-19       Impact factor: 5.071

3.  Bone biomarkers in koalas: validation of assays and preliminary analyses.

Authors:  Chien-Jung Chen; Stephen T Anderson; Natasha Steiger; Allan McKinnon; Joerg Henning; Rachel Allavena
Journal:  J Vet Diagn Invest       Date:  2020-09-11       Impact factor: 1.279

4.  Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia.

Authors:  Raquel Sanabria-de la Torre; Luis Martínez-Heredia; Sheila González-Salvatierra; Francisco Andújar-Vera; Iván Iglesias-Baena; Juan Miguel Villa-Suárez; Victoria Contreras-Bolívar; Mario Corbacho-Soto; Gonzalo Martínez-Navajas; Pedro J Real; Cristina García-Fontana; Manuel Muñoz-Torres; Beatriz García-Fontana
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-14       Impact factor: 6.055

Review 5.  Hypophosphatasia: A Unique Disorder of Bone Mineralization.

Authors:  Juan Miguel Villa-Suárez; Cristina García-Fontana; Francisco Andújar-Vera; Sheila González-Salvatierra; Tomás de Haro-Muñoz; Victoria Contreras-Bolívar; Beatriz García-Fontana; Manuel Muñoz-Torres
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

6.  A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia.

Authors:  Volha V Zhukouskaya; Louisa Jauze; Séverine Charles; Christian Leborgne; Stéphane Hilliquin; Jérémy Sadoine; Lotfi Slimani; Brigitte Baroukh; Laetitia van Wittenberghe; Natalie Danièle; Fabienne Rajas; Agnès Linglart; Federico Mingozzi; Catherine Chaussain; Claire Bardet; Giuseppe Ronzitti
Journal:  Sci Adv       Date:  2021-10-27       Impact factor: 14.136

7.  Bone-turnover biomarkers as potential prognostic factors in sudden sensorineural hearing loss: A prospective cohort study.

Authors:  Xiaoyan Chen; Zhong Zheng; Lili Xiao; Chengqi Liu; Ying Shen; Ning Ma; Hongjun Dong; Shankai Yin; Yanmei Feng
Journal:  Front Neurol       Date:  2022-08-25       Impact factor: 4.086

8.  Pain and health-related quality of life in patients with hypophosphatasemia with and without ALPL gene mutations.

Authors:  Maite Santurtún; Eva Mediavilla-Martinez; Ana I Vega; Natalia Gallego; Karen E Heath; Jair A Tenorio; Pablo Lapunzina; Leyre Riancho-Zarrabeitia; José A Riancho
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

9.  Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.

Authors:  Denise M van de Laarschot; Malachi J McKenna; Bo Abrahamsen; Bente Langdahl; Martine Cohen-Solal; Núria Guañabens; Richard Eastell; Stuart H Ralston; M Carola Zillikens
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

10.  Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa.

Authors:  L Seefried; D Rak; A Petryk; F Genest
Journal:  Osteoporos Int       Date:  2021-07-02       Impact factor: 4.507

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.